"Dose-painting": Myth or reality?

被引：24
|
作者：
Supiot, S. [1 ,2 ,3 ]
Lisbona, A. [2 ,3 ,4 ]
Paris, F. [1 ,2 ,3 ]
Azria, D. [5 ]
Fenoglietto, P. [6 ]
机构：
[1] Ctr Rene Gauducheau, Serv Radiotherapie, F-44800 Nantes, France
[2] Univ Nantes, CRCNA, Inst Rech Therapeut, F-44007 Nantes, France
[3] INSERM, UMR 892, F-44007 Nantes, France
[4] Ctr Rene Gauducheau, Serv Radiophys, F-44800 Nantes, France
[5] Ctr Val Aurelle Paul Lamarque, Serv Radiotherapie, F-34298 Montpellier 5, France
[6] Ctr Val Aurelle Paul Lamarque, Serv Radiophys, F-34298 Montpellier 5, France
来源：
CANCER RADIOTHERAPIE | 2010年 / 14卷 / 6-7期
关键词：
IGRT; Radioresistance; Positron emission tomography; Magnetic resonance spectroscopic imaging; Theragnostics; POSITRON-EMISSION-TOMOGRAPHY; HIGH-GRADE GLIOMAS; INTENSITY-MODULATED RADIOTHERAPY; DOMINANT INTRAPROSTATIC LESIONS; NEWLY-DIAGNOSED GLIOBLASTOMA; CONFORMAL RADIATION-THERAPY; CANCER STEM-CELLS; PROSTATE-CANCER; NECK-CANCER; ACCELERATED RADIOTHERAPY;
D O I：
10.1016/j.canrad.2010.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
"Dose-painting" radiotherapy allows for a heterogeneous delivery of radiation within the tumour volume by targeting radioresistant areas defined by functional imaging. Within gross tumour volume, it is possible to define one or more target volumes based on biology (biological target volume [BTV]) and to apply a strategy of intensity modulated radiation therapy (IMRT) that will deliver a higher dose to these regions. In this review of the literature, we will highlight the biological elements responsible for radioresistance, and how to image them, then we will detail the radiotherapy techniques necessary for this approach, before presenting clinical results in various situations (head and neck tumours, prostate, brain tumours, etc.). Despite many difficulties that make dose-painting IMRT unusable in routine nowadays, biology-guided radiation therapy represents one of the major pathways of development of radiotherapy in the coming years. (C) 2010 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：554 / 562
页数：9
相关论文
共 50 条
  • [31] Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer
    Olteanu, Luiza Ana Maria
    Duprez, Frederic
    De Neve, Wilfried
    Berwouts, Dieter
    Vercauteren, Tom
    Bauters, Wouter
    Deron, Philippe
    Huvenne, Wouter
    Bonte, Katrien
    Goethals, Ingeborg
    Schatteman, Julie
    De Gersem, Werner
    [J]. ACTA ONCOLOGICA, 2018, 57 (02) : 262 - 268
  • [32] Novel Definitive Hypofractionated Accelerated Radiation Dose-painting (HARD) for Unresected Soft Tissue Sarcomas
    Bryant, John Michael
    Mills, Matthew N.
    Yang, George Q.
    Liveringhouse, Casey
    Palm, Russell
    Johnstone, Peter A.
    Miller, Justin T.
    Latifi, Kujtim
    Feygelman, Vladimir
    Naghavi, Arash O.
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2024, 9 (04)
  • [33] HYPOFRACTIONATED DOSE-PAINTING INTENSITY MODULATED RADIATION THERAPY WITH CHEMOTHERAPY FOR NASOPHARYNGEAL CARCINOMA: A PROSPECTIVE TRIAL
    Bakst, Richard L.
    Lee, Nancy
    Pfister, David G.
    Zelefsky, Michael J.
    Hunt, Margie A.
    Kraus, Dennis H.
    Wolden, Suzanne L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (01): : 148 - 153
  • [34] Dose-Painting Sbrt On Tumor-Vessel And Duodenal Interface For Pancreatic Cancer: Dosimetric Analysis
    Caravatta, L.
    Lucarelli, M.
    Augurio, A.
    Rosa, C.
    Trignani, M.
    Genovesi, D.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1086 - S1087
  • [35] Acute Toxicity in ARTFORCE: A Randomized Phase III Dose-Painting Trial in Head and Neck Cancer
    Leeuw, A. D.
    Giralt, J.
    Tao, Y.
    Benavente, S.
    Nguyen, T. V. F.
    Hoebers, F. J. P.
    Hoeben, A.
    Terhaard, C.
    Lee, L. W.
    Friesland, S.
    Steenbakkers, R. J. H. M.
    Kayembe, M. T.
    van Kranen, S.
    Bartelink, H.
    Sonke, J. J.
    Hamming-Vrieze, O.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S98 - S98
  • [36] Predictive value of MR spectroscopic imaging for relapse site in GBM and integration in a dose-painting trial
    Laprie, A.
    Moyal, E. Cohen-Jonathan
    Filleron, T.
    Ken, S.
    Vieillevigne, L.
    Deviers, A.
    Laruelo, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S175 - S176
  • [37] Using spatial information about recurrence risk for robust optimization of dose-painting prescription functions
    Bender, Edward T.
    [J]. MEDICAL PHYSICS, 2012, 39 (05) : 2713 - 2720
  • [38] A novel concept to tumour targeting: inverse dose-painting or targeting the "Low uptake drug volume"
    Yaromina, A.
    Granzier, M.
    Van Elmpt, W.
    Biemans, R.
    Lieuwes, N.
    Dubois, L.
    Lambin, P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S179 - S179
  • [39] Radiomics study from the dose-painting multicenter phase III trial on newly diagnosed glioblastoma
    Tensaouti, F.
    Bailleul, J.
    Martin, E.
    Desmoulin, F.
    Ken, S.
    Desrousseaux, J.
    Vieillevigne, L.
    Lotterie, J.
    Lubrano, V.
    Catalaa, I.
    Noel, G.
    Truc, G.
    Sunyach, M.
    Charissoux, M.
    Magne, N.
    Auberdiac, P.
    Filleron, T.
    Peran, P.
    Moyal, E. Cohen-Jonathan
    Laprie, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S518 - S519
  • [40] Modeling Nanoparticle-Eluting Spacer Degradation During Brachytherapy Application with in Situ Dose-Painting
    Boateng, F.
    Ngwa, W.
    [J]. MEDICAL PHYSICS, 2016, 43 (06) : 3690 - 3691
12345